Storm at the Time of Corona: A Glimpse at the Current Understanding and Therapeutic Opportunities of the Sars-Cov-2 Cytokine Storm Publisher Pubmed



Torabirahvar M¹ ; Rezaei N^{1, 2, 3}
Source: Current Pharmaceutical Design Published:2021

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may lead to severe disease in some cases, leading to acute respiratory distress syndrome, multi-organ failure, and death. This severe phenotype seems to be associated with a cytokine storm and immune dysregulation. Increased pro-inflammatory cytokines and CD14+ CD16+ inflammatory monocytes, lymphopenia, and decreased levels of regulatory T cells are some of the immunological features that are seen in patients with SARS-CoV-2. As the outcome of SARS-CoV-2 is influenced by both viral virulence and dysregulated inflammatory response, a combination therapy approach using antiviral drugs plus anti-inflammatory treatments, such as corticosteroids, monoclonal antibodies against the IL-6 and IL-1β pathways, and JAK inhibitors are under clinical trials. © 2021 Bentham Science Publishers.